Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...

Novo Nordisk has reported new data with its long-acting human growth hormone (hGH) product Sogroya, showing it is at least as effective as its older drug Norditropin in various paediatric growth ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders. The Danish pharmaceutical giant said the drug was more effective ...

(RTTNews) - Novo Nordisk A/S (NVO), Monday announced data from the phase 3 REAL8 basket study, a part of the ongoing REAL clinical trial, evaluating the efficacy and safety of once-weekly Sogroya ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya (somapacitan) in four different but related growth disorder indications ...

Sogroya showed 11.0 cm/year growth in SGA children vs 9.4 cm/year with low-dose somatropin and 11.1 cm/year with high-dose. In Noonan syndrome, Sogroya achieved 10.4 cm/year height gain vs 9.2 cm ...